Relmada Therapeutics, Inc. · NASDAQ:RLMD
Shenouda Maged bought 200,000 Relmada Therapeutics, Inc. shares (Form 4)
Traded Sep 9 to Sep 10, 2026 · Filed Sep 11, 2026
From Sep 9 to Sep 10, 2026, Shenouda Maged (Chief Financial Officer) bought 200,000 Relmada Therapeutics, Inc. shares at an average US$4.22 for US$844K, leaving 1,000,000 shares. Filed Sep 11, 2026 (Form 4).
- Bought
- 200,000 shares
- Price
- US$4.22 average (US$4.20 to US$4.25)
- Value
- US$844K
- Holding after
- 1,000,000 shares
- Trading plan
- No
- Role
- Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Common Stock | Buy | 120,200 | US$4.20 | 920,200 | Direct |
| Sep 10, 2026 | Common Stock | Buy | 79,800 | US$4.25 | 1,000,000 | Direct |
Source
Related
- Relmada Therapeutics, Inc.
- Shenouda Maged
- Relmada Therapeutics, Inc. shareholders
- Form 4 · Traversa Sergio · Sep 11, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2026
- Schedule 13G · BlackRock, Inc. · Jul 29, 2026
- Schedule 13G · Millennium Management LLC · Jun 22, 2026
- Schedule 13G · Venrock Healthcare Capital Partners III, L.P. · Jun 9, 2026